Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G47delta intratumoral therapy for newly diagnosed metastatic prostate cancer
jRCTs033210603Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2022
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of teserpaturev in prostate cancer (PCa), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 1-year failure-free survival rate. Started Feb 2022; status: recruiting.
02
Drugs
teserpaturev
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs033210603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs033210603.